Abstract
Non prostatic tartarate resistant acid phosphatase(TRACP) is present in bone resorbing osteoclasts. Matrix degradation products together with TRACP are released from the osteoclasts into the blood circulation. Therefore this study is carried out to study TRACP as a marker for osteoporosis and bone malignancy. A total of 75 subjects were included in this study. They were divided into 3 groups. Group I included 25 diagnosed cases of malignant bone tumors between the age group 20 to 70 years of both sexes. Group II included 25 cases of osteoporosis and group III, the control group, included 25 healthy individuals of the same age groups and sexes. TRACP was estimated in the serum of all the subjects. TRACP levels were highly increased in both the osteoporosis and bone malignancy groups (p<0.001). Therefore TRACP can be considered as a marker for bone resorption in osteoporosis and bone malignancy.
| Original language | English |
|---|---|
| Journal | International Journal of Pharma and Bio Sciences |
| Volume | 5 |
| Issue number | 3 |
| Publication status | Published - 01-01-2014 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biotechnology
- Biochemistry
- Molecular Biology
- Cell Biology
Cite this
}
Tartarate resistant acid phosphatase as a marker in osteoporosis and bone malignancy. / Rajeshwari; D'Souza, Benedicta; D'Souza, Vivian.
In: International Journal of Pharma and Bio Sciences, Vol. 5, No. 3, 01.01.2014.Research output: Contribution to journal › Article
TY - JOUR
T1 - Tartarate resistant acid phosphatase as a marker in osteoporosis and bone malignancy
AU - Rajeshwari,
AU - D'Souza, Benedicta
AU - D'Souza, Vivian
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Non prostatic tartarate resistant acid phosphatase(TRACP) is present in bone resorbing osteoclasts. Matrix degradation products together with TRACP are released from the osteoclasts into the blood circulation. Therefore this study is carried out to study TRACP as a marker for osteoporosis and bone malignancy. A total of 75 subjects were included in this study. They were divided into 3 groups. Group I included 25 diagnosed cases of malignant bone tumors between the age group 20 to 70 years of both sexes. Group II included 25 cases of osteoporosis and group III, the control group, included 25 healthy individuals of the same age groups and sexes. TRACP was estimated in the serum of all the subjects. TRACP levels were highly increased in both the osteoporosis and bone malignancy groups (p<0.001). Therefore TRACP can be considered as a marker for bone resorption in osteoporosis and bone malignancy.
AB - Non prostatic tartarate resistant acid phosphatase(TRACP) is present in bone resorbing osteoclasts. Matrix degradation products together with TRACP are released from the osteoclasts into the blood circulation. Therefore this study is carried out to study TRACP as a marker for osteoporosis and bone malignancy. A total of 75 subjects were included in this study. They were divided into 3 groups. Group I included 25 diagnosed cases of malignant bone tumors between the age group 20 to 70 years of both sexes. Group II included 25 cases of osteoporosis and group III, the control group, included 25 healthy individuals of the same age groups and sexes. TRACP was estimated in the serum of all the subjects. TRACP levels were highly increased in both the osteoporosis and bone malignancy groups (p<0.001). Therefore TRACP can be considered as a marker for bone resorption in osteoporosis and bone malignancy.
UR - http://www.scopus.com/inward/record.url?scp=84904892474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904892474&partnerID=8YFLogxK
M3 - Article
VL - 5
JO - International Journal of Pharma and Bio Sciences
JF - International Journal of Pharma and Bio Sciences
SN - 0975-6299
IS - 3
ER -